Can Fite Biopharma
Update in progressCANF (NYSE American)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Can-Fite BioPharma Ltd is a clinical-stage biopharma company in Israel developing orally bioavailable small-molecule therapeutics for cancer, liver inflammation, and erectile dysfunction. Lead candidate Piclidenoson completed Phase III for psoriasis. Namodenoson is in Phase III for liver cancer, Phase IIa for pancreatic cancer, and Phase IIb for metabolic-associated steatohepatitis. CF602 is preclinical for erectile dysfunction. License with CMS Medical. Based in Ramat Gan; founded 1994. Formerly Can-Fite Technologies Ltd (name change in 2001).
Company score
- Sentiment
- 0.36
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.18
- Governance
- 0.08
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.07
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.21
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNYSE American (ASE)
- LocationIsrael
- CEOMr. Motti Farbstein
- Founded1994
- Employees5
- Websitewww.canfite.com
Identifiers
- ISINUS13471N2018
- FIGIBBG003CMFDM2
- LEI549300ZLRH6GSBOHFZ59
- CUSIP13471N102
- CIK0001536196